To determine whether lipoxygenase products of arachidonic acid metabolism are released in vivo during human allergic cutaneous reactions, we serially assayed chamber fluid placed over denuded skin sites for the presence of both C-6 peptide leukotrienes (e.g., LTC4, LTD4, and LTE4) and leukotriene B4 (LTB4), using radioimmune assay and HPLC separation, and compared it to histamine (assayed radioenzymatically) in 13 atopic and two nonatopic volunteers. Skin chamber sites challenged with ragweed or grass pollen antigen (250-750 protein nitrogen units/ml) for the first hour and phosphate-buffered saline (PBS) for the next 3 h were assayed hourly and compared to sites challenged with PBS alone. As assessed by HPLC, LTC4 composed greater than 85% of the C-6 peptide leukotriene released at any skin site, whereas little LTD4 or LTE4 was detected. LTC4 was present in significantly greater concentrations at antigen sites as compared to PBS-challenged sites throughout the 4-h period. Minimal concentrations of LTB4 were found throughout this time period and were not different at antigen or PBS sites. Histamine was present in significantly greater concentrations at antigen rather than PBS sites, but the pattern of release was different from that of LTC4. Peak histamine release invariably occurred during the first hour and decreased progressively thereafter, whereas the greatest amounts of LTC4 were detected during the 2nd to 4th hours. 
Introduction
The C6-peptide leukotrienes LTC4, LTD4, and LTE4, formerly defined by their biologic activity as slow reacting substance of anaphylaxis (SRS-A), are lipoxygenase metabolites of arachidonic acid that are thought to play an important role in Receivedfor publication 7 February 1985. human mast cell-mediated reactions. They are potent mediators of bronchoconstriction, vascular and nonvascular smooth muscle constriction, increased vascular permeability, and epithelial mucus secretion (1) . Leukotriene B4 (LTB4) may also be an important allergic mediator, as it stimulates neutrophil and eosinophil chemotactic activity, as well as their aggregation, secretion of lysosomal constituents, and adherence to vascular endothelium (1) . In vitro studies have demonstrated that many cells, including mast cells, neutrophils, eosinophils, basophils, and alveolar macrophages, are capable of generating leukotrienes (LTs)' (2) . Mast cells and Langerhans cells are among the resident cell population in the skin. Our laboratory has found a prominent accumulation of neutrophils, eosinophils, and mononuclear cells during the course of cutaneous allergic reactions (3) . Therefore, the skin provides an ideal site to investigate the profile and temporal pattern of LTs released during ongoing allergic reactions. We have studied the release of the C6 peptide LTs and LTB4 in the skin of atopic subjects during challenge with ragweed or grass pollen extract. We found that LTC4 is the LT present in largest amounts during such reactions; here, we compare its release to that of histamine.
Methods
Patients. 13 atopic and two nonatopic healthy volunteers gave informed consent before study. Atopic subjects fulfilled the following criteria: (a) a history of allergic rhinitis during the fall and/or spring seasons; (b) a positive skin test, defined as a wheal of at least 10-mm diameter in response to an intradermal injection of 0.02 ml of 10 protein nitrogen units (PNU) per milliliter grass or ragweed pollen extract (Greer Laboratories, Lenoir, NC); and (c) no history of previous immunotherapy. Nonatopic subjects had no history of allergic rhinitis and had negative skin tests in response to intradermal injections of 0.02 ml of 1,000 PNU/ml grass and ragweed pollen extracts. No subject had urticaria or atopic dermatitis and no medicines were ingested for at least 72 h before study. The degree of antigen sensitivity of individual subjects was assessed by the extinction dilution skin test titer (EDST). EDST was defined as the greatest 10-fold dilution of relevant pollen extract that would elicit a positive skin test (4) . Seven subjects were sensitive to an EDST of 10 PNU/ml, three to an EDST of 1 PNU/ml, and three to an EDST of 0.1 PNU/ml.
Epicutaneous antigen challenge. 20 epicutaneous antigen challenges were performed on 13 atopic and two nonatopic subjects according to methods described previously (4) . Using mild heat and suction, two 1-cm diameter blisters were raised on each forearm. The blisters were aseptically unroofed and a sterile plastic collection chamber was taped in place over each blister base. To wash away any mediators released by induction of the blister itself, each chamber was filled with sterile isotonic phosphate-buffered saline (PBS); after 5 min, the PBS was removed and discarded. Incubations were then performed in the appended chambers according to the following protocols. Protocol I: simultaneously, two blister bases were incubated for I h with 0.3 ml of 500 PNU/ml grass or ragweed pollen extract and two control sites were incubated with PBS. The chambers were removed at the end of the 1-h incubation period; the blister bases were aspirated dry; fresh chambers were taped in place; and all chambers were filled with 0.3 ml PBS. The contents were removed after I h and the procedure was repeated in this way, a total of four serial 1-h incubations was performed at each site. Protocol II: chambers were removed and replaced at hourly intervals as described above. During the first hour, one site each was incubated with 0.3 ml of 250 PNU/ml pollen extract, 500 PNU/ml pollen extract, 750 PNU/ml pollen extract, or PBS. For the subsequent three incubation periods, PBS was placed in all four chambers. In protocol I, paired antigen-challenged sites and paired PBS-challenged sites, respectively, were pooled for subsequent mediator assay. In both protocols, fluids were aliquoted and frozen at -20'C for histamine assay and at -70'C after being gassed with nitrogen for LT assays.
A recovery experiment was performed to determine whether loss of chamber fluid LTB4, LTC4, or LTD4 was excessive in our model either by means of nonspecific sticking to the chamber or blister base, by degradation in the chamber fluids during incubation, or during storage before assay. In two of the atopic subjects, the washed blister bases were incubated for I h with synthetic LTC4, LTD4, LTB4, and PBS. Specific radioimmunoassays were performed on fluids before and after incubation; percent recovery was defined as recovered immunoreactive LT concentration/immunoreactive LT concentration before incubation. In these two subjects, 35% (5.5:16 pmol/ml) and 24% (3.3:14 pmol/ml) of incubated LTC4 was recovered; 56% (36:64 pmol/ ml) and 71% (51:72 pmol/ml) of incubated LTD4 was recovered; 62% (34:56 pmol/ml) and 58% (32:55 pmol/ml) of incubated LTB4 was recovered. None of the LTs was present at the PBS site.
Mediator assays. Histamine: histamine concentrations were measured in triplicate by a radioenzymatic technique as previously described (5) . This assay reproducibly detects histamine levels of at least 2 ng/ ml in skin chamber fluids. Leukotrienes: [14,15- Radioimmunoassays for LTs were performed as described with rabbit antisera of high specificity for LTC4 and LTB4 (7, 8) and a rabbit antiserum that recognizes all of the C-6 peptide LTs (Drs. E.
Hayes and A. Rosenthal, Merck Laboratories, Inc., Rahway, NJ) (6), using [3H]LTC4 and synthetic LTC4, H3 of LTB4 and synthetic LTB4 and H3 of LTD4 and synthetic LTC4, LTD4, or LTE4 as the respective pairs of ligands. Each value was corrected for the recovery of radiolabeled compound. The lowest limit of reliable quantification and the amount required for 50% inhibition of the radioligand, respectively, were 0.08 pmol and 0.35 pmol for the LTC4 assay (7) and 0.03 pmol and 0.15 pmol for the LTB4 assay (8) . The same values for the C-6 peptide LT assay were dependent on the unlabeled LT employed to displace [3H]LTD4 and were 0.1 and 0.7 pmol for LTC4, 0.2 and 1.3 pmol for LTD4, and 0.5 and 6.8 pmol for LTE4. LTC4 was used as the competing ligand to develop the standard curve from which values were calculated for analyses of samples before HPLC. Three separate standard curves appropriate for the different regions of the eluate from HPLC were developed using LTC4, LTD4, and LTE4, respectively, to displace [3H]LTD4 (Fig. 1) . In all cases in which sufficient fluid was available (31 of 100 fluids from antigen challenged sites and 25 of 52 fluids from PBS-challenged sites), chamber fluids were assayed for C-6 peptide LT, LTC4, and LTB4 both before and after HPLC coelution with synthetic standard LTB4, LTC4, and LTD4. A mean of 95% of the [3HJLTC4 was recovered after HPLC with a correlation coefficient of 0.91 (P < 0.001) between LTC4 values before and after HPLC.
LT and histamine accumulations were expressed as concentrations (pmol/ml and ng/ml, respectively). The absolute amount ofaccumulated mediator over the 4-h period was determined by multiplying the sum of the concentrations in the hourly collections by the volume of fluid in the chambers, 0.3 ml.
Results
Seven atopic and two nonatopic subjects were studied with Protocol I to determine whether radioimmunoreactive C-6 peptide LTs or LTB4 were released in response to cutaneous antigen challenge. Assays for immunoreactive C-6 peptide LTs were performed on all chamber fluids, while assays for immunoreactive LTB4 were performed only on fluids obtained from atopic subjects. More total (Table I) Having ascertained that epicutaneous antigen challenge caused the release of immunoreactive C-6 peptide LTs, we next performed HPLC on selected fluids from antigen-challenged sites followed by specific radioimmunoassays (RIA) for LTB4, LTC4, and a combination, LTC4-D4-E4. As shown in one representative analysis of the eluate from HPLC (Fig. 1) , most of the immunoreactive C-6 peptide LT consisted of LTC4 with little LTD4; the quantity of LTB4 also was small. The values for the LTC4-D4-E4 immunoreactivities eluting at 7-9 min and 27-28 min were calculated using the LTD4 standard curve, but probably represent sulfur oxidation products of the C-6 peptide LTs and LTE4, respectively, based on the times of elution relative to synthetic standards. Using an LTE4 standard curve, the quantity of presumptive LTE4 detected in HPLC eluates of these samples and of singlicate samples from four other patients were 0.65±0.17 pmol/ml (mean±SD) relative to 7.7±2.2 pmol/ml of LTC4. RIA of eluted LTC4 and LTD4 peaks demonstrated that a mean of 93% (range = 67-100%) of the C-6 peptide LTs consisted of LTC4 and 7% (range = 0-33%) consisted of LTD4 (Table II) . In all cases involving protocols I and II in which sufficient fluid was available (31 of 100 fluids from antigen-challenged sites and 25 of 52 fluids from PBS challenged sites) assays were performed for C-6 peptide LT, LTC4, and LTB4 both before and after HPLC coelution with synthetic standard LTB4, LTC4, and LTD4. In this larger group of samples >85% of the immunoreactive C-6 peptide LT was LTC4 and 10% was LTD4, minimal amounts of LTB4 were detected.
Having determined that LTC4 is the predominant C-6 peptide LT present in chamber fluids following epicutaneous antigen challenge, we examined the time-course of LTC4 release during the 4-h study period. In five of the seven subjects in protocol I, for whom the quantity of fluid was sufficient, and in all six subjects in protocol II, the levels of specific LTC4 were assayed by a monospecific RIA in chamber fluids collected hourly at sites incubated with antigen or PBS during the first hour followed by PBS incubation at each site for the subsequent 3 h. The LTC4 levels (Table III) were significantly higher in fluids collected each hour at sites challenged with antigen than in those challenged with PBS. Although the temporal patterns of release varied among subjects, release was generally sustained throughout the 4-h collection period, with higher levels tending to occur during the second to fourth hours of incubation. At PBS challenged sites, a similar temporal pattern of LTC4 release was noted for the group as a whole, with the values at 2 h being significantly higher than at I h.
Chamber fluid histamine was present in significantly greater concentrations at antigen than PBS-challenged sites (Table  IV) . For all subjects, the highest concentration was present in the first hour with decreasing concentrations thereafter. This temporal pattern was quite different than the pattern of sustained release over 4 h of LTC4 at the same sites.
Protocol II was designed to determine whether LTC4 release is antigen dose-dependent. Six atopic subjects (numbers 8-13) were studied. As shown in Fig. 2 , greater total and hourly concentrations of LTC4 were measured at antigenchallenged rather than PBS-challenged sites. The greatest LTC4 accumulations were seen at sites challenged with 500 PNU/ ml antigen solutions (mean = 3.0±0.30), with significantly less total LTC4 at sites challenged with 250 PNU/ml of antigen (mean = 1.4±0.55, P . 0.05). The dose-response relationship was most apparent during hours 2-4 of collection of chamber fluids, whereas concentrations of LTC4 were similar during the first hour at all antigen-challenged sites. Unlike LTC4, histamine was not released into chamber fluids in a dosedependent response manner within this range of antigen concentrations (Fig. 3) .
At sites challenged with 500 PNU/ml antigen where accumulated LTC4 was at peak concentrations and histamine was at a plateau level, there was no correlation between hourly or total fluid histamine and LTC4 concentrations in individual chamber fluids. In addition, no correlations were found between hourly or total chamber LTC4 or histamine accumulation and subject sensitivity as measured by EDST.
Discussion
The findings described have indicated that significantly greater amounts of C-6 peptide LT are released into skin chambers for at least 4 h after epicutaneous antigen challenge as compared with the amounts released at control skin sites. LTC4 accounted for >85% of the C-6 peptide LT with little LTD4 or LTE4 detected. Essentially, no chamber fluid LTB4 was found at either antigen-or control-challenged sites. Chamber fluid concentrations of LTC4 were significantly elevated during the entire 4 h of incubation; and although temporal patterns varied among individuals for the group as a whole, the greatest amounts were detected during the second, third, and fourth hours of incubation. This pattern of release differed from that of histamine, in which the greatest concentrations were obtained during the first hour with progressively decreasing concentrations in fluids collected during hours 2-4.
Many cell types have been demonstrated to be capable of generating C-6 peptide LTs and LTB4: human lung mast cells (9) and eosinophils (10-12) release predominantly LTC4 and little LTB4, whereas neutrophils (10-13) and alveolar macrophages (14, 15) produce a substantial quantity of LTB4. Human monocytes generate up to 3.5 times more LTB4 than LTC4 (16). Using skin biopsies, our laboratory has previously documented the timing of progressive cellular infiltration Figure 2 . Hourly chamber fluid LTC4: dose response characteristics. Mean and standard deviation of chamber fluid LTC4 (pmol/ml) of six subjects is represented on the ordinate, the time of collection after 750, 500, and 250 PNU/ml of antigen or buffer (PBS) on the abcissa.
The total LTC4 release (sum of all hours X 0.3 ml) is represented by the 5th bar. * represents P < 0.05 + P < 0.01 ++ P < 0.001 from buffer sites. is conceivable that LTB4 might be catabolized effectively before it could diffuse into the chamber fluids in measurable amounts. Eosinophils might contribute to LTC4 detected during the third and fourth hours, but are probably not present in sufficient numbers in the first 2 h to account for the earlier accumulation of LTC4. Our laboratory has previously reported the release of histamine in progressively decreasing amounts during a 4-h period in ongoing allergic reactions (4) . In that report, we suggested that the prolonged release of histamine represented continuing mast cell activity and that other mast cell-derived mediators might also be released for prolonged periods during ongoing allergic reactions. The findings reported here are additional, although circumstantial, evidence that mast cells might be the primary source of the LTC4 detected at antigen-challenged sites in the present study.
The amount of chamber fluid LTC4 that was recovered was related to the amount of antigen incubated with a peak response following the 500 PNU/ml epicutaneous antigen challenge. Previous studies in our laboratory have demonstrated that chamber fluid histamine accumulation and the degree of neutrophilic leukocyte infiltration into epicutaneous antigenchallenged skin sites are antigen dose-dependent (17) . In that study, the antigen doses examined were 0, 100, 500, and 1,000 PNU/ml. Perhaps the broader dose range and larger number of subjects used in the former study detected a dose-dependent response for histamine release, not apparent with the use of narrower antigen dose range in the study reported here.
However, the temporal pattern of release of LTC4 was different from that of histamine. Whereas peak histamine release invariably occurs during the first hour and progressively decreases thereafter, LTC4 release was relatively constant after the first hour. This difference is most readily explained by the fact that histamine is present within mast cell granules as a pre-formed mediator, whereas LTC4 must be generated after perturbation of the cell membrane and release of arachidonic acid by lipoxygenase metabolism.
A substantial amount of in vitro evidence has been accumulated that suggests a major role for the lipoxygenase products of arachidonic acid metabolism in allergic as well as nonallergic inflammatory diseases. However, to clearly demonstrate a pathophysiologic role for the LTs, Koch's postulates must be fulfilled. The availability of synthetic LTs has permitted experiments which indicate that the LTs can reproduce many features of allergic disease. Inhalation of LTC4 (18, 19) and LTD4 (19, 20) by humans causes bronchoconstriction. Intracutaneous injections of LTC4, LTD4, or LTE4 cause a wheal and a flare that persists for as long as 2 and 6 h, respectively (21, 22 
